Welcome to our dedicated page for ENDP news (Ticker: ENDP), a resource for investors and traders seeking the latest updates and insights on ENDP stock.
Endo International plc (OTC: ENDPQ) maintains this comprehensive news hub to keep stakeholders informed about developments in specialty pharmaceuticals. Our curated collection features official press releases and verified updates directly impacting the company's operations and therapeutic innovations.
Visitors will find timely information on clinical trial progress, including collagenase clostridium histolyticum (CCH) research for plantar fibromatosis, regulatory milestones, strategic partnerships, and financial restructuring updates. The resource prioritizes verified updates across Endo's core therapeutic areas: pain management, urology, endocrinology, and oncology.
This centralized news source enables efficient tracking of both scientific advancements and organizational developments. All content undergoes rigorous verification to ensure accuracy and relevance for investment research and industry analysis.
Bookmark this page for direct access to Endo's latest announcements. For additional corporate information, visit the official Endo International website.
On October 22, 2021, Endo International plc (NASDAQ: ENDP) shared new post-hoc data from two Phase 3 studies of XIAFLEX® for Peyronie's disease at the SMSNA annual meeting. The analysis highlighted the significance of patient adherence and incremental benefits from each of the four treatment cycles, suggesting that consistent treatment improves outcomes for men, even for those initially considered non-responders. XIAFLEX is the only FDA-approved non-surgical treatment for this condition, affecting an estimated 1 in 10 men in the U.S.
Endo International (NASDAQ: ENDP) will release its Q3 2021 financial results on November 4, 2021. Following the earnings announcement, the company's senior management will host a conference call on November 5, 2021 at 7:30 am ET. Investors can access the call via U.S./Canada dial-in (866) 497-0462, or internationally at (678) 509-7598 using passcode 6052178. A replay will be available from November 5, 2021, to November 12, 2021. For more details, visit endo.com.
Endo International (NASDAQ: ENDP) announced a $7.5 million agreement to settle all opioid-related claims with the Louisiana Attorney General's office. The settlement requires 100% participation from Louisiana’s political subdivisions by October 28, 2021, and includes no admission of wrongdoing by Endo. This effort is part of Endo's broader strategy to resolve ongoing opioid litigation while pursuing other strategic options. The company aims to help address Louisiana’s opioid crisis through these funds.
Endo International announced that Par Pharmaceutical has begun shipping the first FDA-approved generic version of Pfizer's Chantix (varenicline) in the U.S. This significant milestone follows the final approval of its Abbreviated New Drug Application. Estimated sales of Chantix were approximately $1 billion for the 12 months ending June 30, 2021. Jon Holden, Endo's Senior VP, emphasized the importance of this launch in expanding Par's product portfolio and providing reliable generics to the market.
Endo International plc (NASDAQ: ENDP) announced a settlement regarding three opioid-related lawsuits in New York, resolving claims against its subsidiaries for $50 million. This settlement severs Endo from an ongoing jury trial that began in June 2021, without admitting any wrongdoing. The company aims for a global settlement for remaining opioid claims and is exploring strategic alternatives if this is not achieved. The settlement should not be seen as a precedent for other cases or claims.
Endo International (NASDAQ: ENDP) expressed disappointment over the U.S. District Court's ruling favoring Eagle Pharmaceuticals regarding VASOSTRICT® patent litigation. The court ruled there was no infringement on Endo's patents by Eagle's proposed product but did not address the validity of these patents. Endo plans to appeal the decision, highlighting concerns over the court's interpretation of conflicting appellate case law on product testing data. The company remains committed to defending its intellectual property rights.
Endo International plc (NASDAQ: ENDP) reported second-quarter 2021 results with total revenues of $714 million, a 4% increase from $688 million in Q2 2020. The Branded Pharmaceuticals segment saw strong growth, with XIAFLEX® revenues rising to $111 million from $34 million year-over-year. However, the company reported a net loss of $15.5 million and a diluted net loss per share of $0.04. Endo adjusted its full-year financial guidance, reflecting uncertainties related to the ongoing COVID-19 pandemic.
Endo International plc (NASDAQ: ENDP) announced a definitive Settlement Agreement resolving an opioid-related case, Staubus, et al. v. Purdue Pharma, L.P., et al., in Sullivan County, Tennessee. The settlement, totaling $35 million, resolves all related claims from nine counties and eighteen towns, with no admission of wrongdoing by Endo. This agreement is designed to absolve Endo from related lawsuits but should not set a precedent for other claims. The financial impact is significant, although details regarding how the payment will be distributed among plaintiffs were not disclosed.
Endo International plc (NASDAQ: ENDP) reported promising Phase I results for collagenase clostridium histolyticum (CCH) as a treatment for plantar fibromatosis at the American Podiatric Medical Association Annual Scientific Meeting. The study involved 24 patients and indicated that CCH was generally well tolerated, with no serious treatment-related adverse events. Over 72% of participants expressed satisfaction with the treatment. This study marks a potential shift for Endo into the podiatric market and builds on their commitment to advancing nonsurgical treatment options.
